
WHAT IS CLAIMED IS:

1. Use of a combination of compounds in the manufacture of a medicament for treating a disease or condition, wherein the combination includes an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, and an effective amount of Compound (B), or a pharmaceutically acceptable salt thereof, wherein:


the Compound (A) has the structure:




(A); and

the Compound (B) is selected from the group consisting of a CDK4/6 inhibitor, a selective aromatase inhibitor, a non-selective aromatase inhibitor, a mTOR inhibitor, a PI3K inhibitor, an ERK or a MEK inhibitor, AKT inhibitor, a BET inhibitor and an Aurora inhibitor, or a pharmaceutically acceptable salt of any of the foregoing;


wherein the CDK4/6 inhibitor is selected from the group consisting of




,



,











and





, or a pharmaceutically acceptable salt of any of the foregoing;









wherein the selective aromatase inhibitor is selected from the group consisting of


,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing;





wherein the non-selective aromatase inhibitor is selected from the group consisting of

and

, or a pharmaceutically acceptable salt of any of the foregoing;








wherein the mTOR inhibitor is selected from the group consisting of






,

,










,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing;

wherein the PI3K inhibitor is selected from the group consisting of









,

,

,

,

, , , , ,  and , or a pharmaceutically acceptable salt of any of the foregoing;









wherein the ERK or the MEK inhibitor is selected from the group consisting of , , , ,



,

,

,

,

,

, KO-947,

and

, or a pharmaceutically acceptable salt of any of the foregoing;

wherein the AKT inhibitor is selected from the group consisting of


,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing;


wherein the BET inhibitor is selected from the group consisting of


,

,

,

,

,

,

,

, JQ1 and




, or a pharmaceutically acceptable salt of any of the foregoing; and


wherein the Aurora inhibitor is selected from the group consisting of




,




,




,










,








,



,


,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing; and

wherein Compound (A), or a pharmaceutically acceptable salt thereof, and Compound (B), or a pharmaceutically acceptable salt thereof, are provided in a single pharmaceutical composition or separate pharmaceutical compositions.

2. The use of Claim 1, wherein the Compound (B) is selected from the group consisting of , , , , JQ1 and , or a pharmaceutically acceptable salt of any of the foregoing.

3. The use of any one of Claims 1-2, wherein the disease or condition is selected from the group consisting of a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer, a vulvar cancer, a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a lung cancer , a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, a Wilms' cancer, a skin cancer, a malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin’s lymphoma.

4. The use of Claim 3, wherein the disease or condition is a breast cancer.

5. The use of Claim 4, wherein the breast cancer does not include any point mutations ER mutations.

6. The use of any one of Claims 4-5, wherein the breast cancer is ER positive breast cancer.

7. The use of any one of Claims 4-5, wherein the breast cancer is ER positive/HER2-negative breast cancer.

8. The use of any one of Claims 4-7, wherein the breast cancer has been previously treated with an endocrine therapy.

9. The use of Claim 8, wherein the treatment was with a selective ER modulator (SERM).

10. The use of Claim 8, wherein the treatment was with a selective ER degrader (SERD).

11. The use of Claim 8, wherein the treatment was with an aromatase inhibitor.

12. The use of any one of Claims 4-7, wherein the breast cancer has not been previously treated.

13. The use of any one of Claim 4-12, wherein the breast cancer is present in a woman.

14. The use of Claim 13, wherein the subject is a premenopausal woman.

15. The use of Claim 13, wherein the subject is a perimenopausal woman.

16. The use of Claim 13, wherein the subject is a menopausal woman.

17. The use of Claim 13, wherein the breast cancer is present in a postmenopausal woman.

18. The use of any one of Claim 4-17, wherein the breast cancer is present in a subject that has a serum estradiol level in the range of >15 pg/mL to 350 pg/mL.

19. The use of any one of Claim 4-17, wherein the breast cancer is present in a subject that has a serum estradiol level ≤ 15 pg/mL.

20. The use of any one of Claim 4-17, wherein the breast cancer is present in a subject that has a serum estradiol level ≤ 10 pg/mL.